Accumen Inc., the leader in healthcare performance, today announced that it has acquired 3DR Laboratories, the largest and most respected 3D medical post-processing laboratory in the United States.

Accumen’s team members work side-by-side with the hospital, health system, commercial laboratory, payer, and pharmacy clients, providing strategic solutions, services and technology that deliver sustainable performance improvements in operations, clinical services, and data management. These offerings include lab and imaging transformation, consulting, supply chain optimization, lab outreach, patient blood utilization, test utilization, anaemia management and clinical data exchange. Accumen’s offerings enable its clients to achieve and exceed - their cost, quality, and service targets, as well as deliver excellent patient care through evidence-based data and clinical decision support capabilities.

The addition of 3DR Laboratories to the Accumen portfolio of companies brings expansion to Accumen’s clinical offerings, as well as depth to its imaging transformation offering, which is focused on operational performance in imaging departments and centers across the country bringing meaningful savings, operational efficiencies and improved patient care.

“We are delighted that 3DR Laboratories is joining our Clinical Performance Business Unit and further strengthening our imaging transformation service line. We are very impressed with the high quality and consistency of 3DR’s computed tomography (CT) and magnetic resonance imaging (MRI) post-processing work, as well as its strong service-centric reputation which is enabling radiologists to meet even the most urgent patient needs,” said Accumen President and CEO Jeff Osborne.

Since it was founded in 2005, 3DR Laboratories has provided post-processing services to hundreds of hospital radiology departments, stand-alone imaging centers, and radiology practices, enabling them to obtain expert processing of their medical imaging cases within hours or even minutes for emergencies. 3DR Laboratories has processed more than 400,000 cases and now has more than 450 active clients nationally.

“At Accumen, we are steadily expanding our portfolio so that we can help our clients to optimize their performance; whether it be operational, clinical, or data-focused. We want to assist all healthcare clients in resolving inefficiencies so they can meet their patient experience goals, while also preparing for continued reimbursement reductions. Our clients can then reinvest the time and cost savings achieved through our partnerships into patient care, so everyone benefits,” added Mr Osborne.

“Accumen is continuing to aggressively invest into its already strong imaging transformation offering and we are excited to have become a key part of their team. This is a great strategic fit because our companies share a similar vision with complementary cultures and values. Furthermore, we will now be able to significantly expand the range of services that we can offer to our clients,” said 3DR’s CEO and Chairman of the Board, David E. Ferguson.

Accumen’s imaging team already has decades of operational and clinical imaging experience. It also has two well-respected radiologists - Dr Carla Harmath and Dr Jonathan Chung from the University of Chicago Medicine - on its Medical Advisory Council. Dr James Brink, Mass General Radiologist-in-Chief is also a member of Accumen’s Board of Directors.       

“Accumen shares our strong commitment to delivering high quality results and excellent customer service. It is also an exciting entrepreneurial, team-focused environment in which our employees will thrive,” said Dr. Robert E. Falk, 3DR founder and Chief Medical Officer.

No changes are expected with respect to 3DR’s excellent staff – currently consisting of more than 150 employees, 120 of which are radiologic technologists – or its Louisville, KY main office.

Underscoring 3DR’s commitment to excellence, all its technologists are specially trained and American Registry of Radiologic Technologists-certified. 3DR also has an extensive, HIPAA-compliant security system to safeguard the transmission of case files.

This is Accumen’s third acquisition since being acquired by Arsenal Capital Partners in January 2019. Accumen acquired Halfpenny Technologies Inc., a provider of clinical data exchange platforms for health systems, commercial labs, and health plans. Accumen also acquired Patient Readiness Institute’s MyBloodHealth^®, a virtual, pre-operative anaemia management solution. 

Edgemont Partners represented 3DR Laboratories and its ownership group through 3DR’s transaction process, and Healthcare Growth Partners (HGP) represented Accumen and Arsenal. No financial details about these transactions have been disclosed.